Drug Combinations for Kidney Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical research study is to compare 6 different 2-drug "sequences" of everolimus, bevacizumab, or pazopanib to learn how they may affect metastatic kidney cancer. For the 2-drug sequence, participants will receive 1 of these drugs and may start taking another of these drugs after that. Researchers will also study the safety of these 2-drug sequences.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot take certain drugs like rifampin, St. John's wort, or specific antiepileptic drugs during the study. It's best to discuss your current medications with the trial team.
Is the drug combination including Pazopanib safe for humans?
How is the drug combination of Bevacizumab, Everolimus, and Pazopanib unique for kidney cancer?
This drug combination is unique because it combines Bevacizumab, which inhibits blood vessel growth in tumors, with Everolimus, an mTOR inhibitor that blocks cancer cell growth, and Pazopanib, a multikinase inhibitor targeting several pathways involved in cancer progression. This multi-targeted approach may offer a broader attack on kidney cancer compared to single-agent therapies.16789
What data supports the effectiveness of the drug combinations for kidney cancer?
Who Is on the Research Team?
Amado Zurita, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
Adults with metastatic renal cell carcinoma (RCC) that includes a clear cell component, who have had surgery or certain other treatments for their primary tumor. They must be able to swallow pills, not have received targeted therapy or chemotherapy for mRCC (though prior immunotherapy is okay), and agree to use birth control. People with active infections, another cancer treatment ongoing, significant heart issues, uncontrolled hypertension or diabetes, severe liver disease, brain metastases (except controlled solitary ones), coagulation disorders on certain anticoagulants are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one of the study drugs (everolimus, bevacizumab, or pazopanib) and may switch to another drug if the disease progresses.
End-of-Treatment
Participants undergo a final assessment after completing the study drug regimen.
Long-Term Follow-Up
Participants are monitored for safety and effectiveness after treatment completion, with follow-ups every 3 months for the first 2 years, every 6 months for the third year, and annually thereafter.
What Are the Treatments Tested in This Trial?
Interventions
- Bevacizumab
- Everolimus
- Pazopanib
Bevacizumab is already approved in European Union, United States, Japan, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
Novartis
Industry Sponsor
Vasant Narasimhan
Novartis
Chief Executive Officer since 2018
MD from Harvard Medical School, Bachelor's in Biological Sciences from University of Chicago, Master's in Public Policy from John F. Kennedy School of Government
Shreeram Aradhye
Novartis
Chief Medical Officer since 2022
MD from Yale University, MSc in Clinical Epidemiology from University of Pennsylvania